Autoimmune myasthenia gravis.
The evident defect in this disease is postsynaptic dysfunction due to anti-acetylcholine receptor antibodies. The postsynaptic membrane is simplified, the number of acetylcholine receptors is reduced, and neuromuscular transmission is impaired. Antiacetylcholinesterase drugs still play a role in management. Newer options include prednisone, azathioprine, and cyclosporine.